Answers are grounded in this paper and cite their sources.
INTRODUCTION: Primary lung mucinous adenocarcinoma (PLMAC) frequently harbors KRAS mutations; however, the distribution of KRAS variants in PLMAC remains under-characterized. This study aimed to investigate the KRAS mutational profile in PLMAC. MATERIALS AND METHODS: Cases of PLMAC (2018-2022) and primary lung nonmucinous adenocarcinomas (PLNMAC) (Oct-Dec 2022) were identified from pathology archives. Molecular testing was performed using a next-generation sequencing lung cancer hotspot gene panel. Specimen types, molecular results, demographic data, and smoking status were recorded. Statistical significance was assessed using an online Z-score calculator. RESULTS: A total of 117 PLMAC and 185 PLNMAC cases were identified. KRAS mutations were more common in PLMAC (62/86, 72%) compared to PLNMAC (61/154, 40%). In PLMAC, the most common KRAS variants were G12V (39%), followed by G12D (32%), while G12C was found in 19%. In PLNMAC, G12C was the predominant variant (47%). Among 27 (23%) never-smoking PLMAC patients, 17 were tested, and 12 (71%) harbored KRAS mutations-all non-G12C. Among 26 (14%) never-smoking PLNMAC patients, 20 were tested, and only one had a KRAS mutation, which was G12C. CONCLUSIONS: In our cohort, KRAS mutations were more prevalent in PLMAC than PLNMAC (72% vs. 40%, P < 0.05). However, the KRAS G12C variant was significantly less frequent in PLMAC compared to PLNMAC (19% vs. 47%, P < 0.05), suggesting that patients with PLMAC are less likely to benefit from KRAS G12C-targeted therapy. These findings underscore the importance of comprehensive KRAS genotyping and highlight the need for developing additional KRAS variant-targeted therapy for patients with PLMAC.
No takes yet. Share an insight, caveat, or question.
Htoo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: